rbs revised report on cxs , page-5

Good report. I keep watching to see if worth entry but not yet.

No doubt significant delays and some costs, so does anyone really believe no capital raising coming?

I wonder what news/(re)positioning will come first? Maybe avoid the diagnostic altogether with data from latest trial (depends if data is good enough)? Maybe announcement of diagnostic strategy (although unlikely to have fda stamp of approval in short term).